Tenaya Therapeutics to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) announced that CEO Faraz Ali will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on October 14, 2025. Company management will hold virtual 1x1 meetings on October 15, 2025. The fireside chat will be webcast and accessible from the Investors section of Tenaya's website, with an archived replay available for approximately 30 days after the conference.
Positive
- None.
Negative
- None.
News Market Reaction 17 Alerts
On the day this news was published, TNYA gained 15.35%, reflecting a significant positive market reaction. Our momentum scanner triggered 17 alerts that day, indicating notable trading interest and price volatility. The stock closed at $2.33 on that trading session. This price movement added approximately $51M to the company's valuation, bringing the market cap to $380M at that time.
Data tracked by StockTitan Argus on the day of publication.
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced that Faraz Ali, Tenaya’s Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Genetic Medicines Virtual Conference on Tuesday, October 14, 2025. Company management will host virtual 1x1 meetings on Wednesday, October 15, 2025.
The webcast of the fireside chat may be accessed from the Investors section of Tenaya’s website. An archived replay of the webcast will be available on the Tenaya website for approximately 30 days following the conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
FAQ
When will Tenaya Therapeutics (TNYA) present at the H.C. Wainwright conference?
How can investors watch Tenaya Therapeutics (TNYA) fireside chat on October 14, 2025?
Will Tenaya Therapeutics (TNYA) provide a replay of the October 14, 2025 webcast?
Who from Tenaya Therapeutics will speak at the H.C. Wainwright Genetic Medicines event?
Will Tenaya Therapeutics (TNYA) host investor meetings at the conference?
Where can I find details and scheduling for Tenaya Therapeutics (TNYA) conference participation?
